Sequential intrapleural administration of fibrinolytic drugs and dornase alfa for empyema management. Treatment protocol based on its physicochemical stability

Objective: Intrapleural administration of fibrinolytics and dornase alfa has been shown in randomized studies to be able to reduce both the need for surgical debridement of empyema and the average hospital stay. However, its application in clinical practice is limited, probably due to the lack of pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Carla Bastida (Author), Carlota Salazar-Santander (Author), Dolors Soy (Author), David Sánchez (Author), Carmen Díez (Author), Joan Ramón Badia (Author)
Format: Book
Published: Elsevier, 2020-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8ae2d8b0b307429e817eb07c897e0fb7
042 |a dc 
100 1 0 |a Carla Bastida  |e author 
700 1 0 |a Carlota Salazar-Santander  |e author 
700 1 0 |a Dolors Soy  |e author 
700 1 0 |a David Sánchez  |e author 
700 1 0 |a Carmen Díez  |e author 
700 1 0 |a Joan Ramón Badia  |e author 
245 0 0 |a Sequential intrapleural administration of fibrinolytic drugs and dornase alfa for empyema management. Treatment protocol based on its physicochemical stability 
260 |b Elsevier,   |c 2020-01-01T00:00:00Z. 
500 |a 10.7399/fh.11276 
500 |a 1130-6343 
500 |a 2171-8695 
520 |a Objective: Intrapleural administration of fibrinolytics and dornase alfa has been shown in randomized studies to be able to reduce both the need for surgical debridement of empyema and the average hospital stay. However, its application in clinical practice is limited, probably due to the lack of protocols that simplify its administration. The present study aims to analyze the physicochemical stability of the simultaneous urokinase and dornase alfa administration for the subsequent development of a clinical practice use protocol. Method: In vitro stability test of urokinase, dornase alfa and a combination of both. Its stability was evaluated as (i) absence of particles, (ii) color variation and (iii) pH changes at times 0, 30 minutes, 1, 2 and 4 hours at 37 °C. Each sample was prepared and analyzed in triplicate. Results: Individual solutions of urokinase and dornase alfa showed slight changes in pH, finding no changes in either color or presence of suspended particles. The urokinase and dornase alfa combination was not stable after 2 hours, when turbidity emerged due to flocculation and phase separation. After 4 hours, precipitate formation was found. A pro tocol for clinical use was developed based on urokinase and dornase alfa sequential administration, since it was not possible to guarantee the physicochemical stability of the simultaneous administration of both drugs. Conclusions: The physicochemical stability data obtained does not allow to ensure a simultaneous administration of both drugs in a safe and effective way, thus a sequential administration protocol is proposed. 
546 |a EN 
546 |a ES 
690 |a dornase 
690 |a dnase 
690 |a empyema 
690 |a protocol 
690 |a intrapleural therapy 
690 |a urokinase 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Farmacia Hospitalaria, Vol 44, Iss 1, Pp 16-19 (2020) 
787 0 |n http://www.aulamedica.es/fh/pdf/11276.pdf 
787 0 |n https://doaj.org/toc/1130-6343 
787 0 |n https://doaj.org/toc/2171-8695 
856 4 1 |u https://doaj.org/article/8ae2d8b0b307429e817eb07c897e0fb7  |z Connect to this object online.